Allogene Therapeutics (ALLO) Current Assets (2018 - 2026)
Allogene Therapeutics (ALLO) posted Current Assets of $273.3 million for Q1 2026, up 6.03% sequentially from $257.7 million in Q4 2025, and down 6.27% YoY from $291.6 million in Q1 2025.
Allogene Therapeutics (ALLO) Current Assets (2018 - 2026) Analysis & Trends
Allogene Therapeutics has reported Current Assets for 9 years, with the latest figure at $273.3 million in Q1 2026.
- Quarterly Current Assets fell 6.27% year-over-year to $273.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $273.3 million (down 6.27% YoY) and the FY2025 annual result came in at $257.7 million, down 15.04% from the prior year.
- Current Assets advanced to $273.3 million in Q1 2026 per ALLO's latest filing, from $257.7 million in the prior quarter.
- Over five years, Current Assets peaked at $569.1 million in Q3 2022 and troughed at $257.7 million in Q4 2025.
- A 5-year average of $401.4 million and a median of $457.1 million in 2024 frame the typical range for Current Assets.
- The sharpest annual moves came in 2022 and 2025: Current Assets grew 13.17% in 2022, then sank 38.17% in 2025.
- Over 5 years, Current Assets stood at $528.8 million in 2022, then dropped by 13.18% to $459.1 million in 2023, then tumbled by 33.92% to $303.4 million in 2024, then declined by 15.04% to $257.7 million in 2025, then climbed by 6.03% to $273.3 million in 2026.
- According to Business Quant data, Current Assets over the past three periods registered $273.3 million, $257.7 million, and $260.7 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 12.54 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 18.45 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 8.07 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 4.03 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 7.22 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 11.83 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 1.76 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 4.62 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 1.63 Bn |
| 10 | Allogene Therapeutics | 707.96 Mn | 707.96 Mn | - | 340.00 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 340.00 Mn |
| Mar 31, 2026 | 273.29 Mn |
| Dec 31, 2025 | 257.75 Mn |
| Sep 30, 2025 | 260.72 Mn |
| Jun 30, 2025 | 282.66 Mn |
| Mar 31, 2025 | 291.58 Mn |
| Dec 31, 2024 | 303.39 Mn |
| Sep 30, 2024 | 304.42 Mn |
| Jun 30, 2024 | 457.12 Mn |
| Mar 31, 2024 | 395.36 Mn |
| Dec 31, 2023 | 459.12 Mn |
| Sep 30, 2023 | 473.45 Mn |
| Jun 30, 2023 | 502.10 Mn |
| Mar 31, 2023 | 481.47 Mn |
| Dec 31, 2022 | 528.82 Mn |
| Sep 30, 2022 | 569.06 Mn |
| Jun 30, 2022 | 513.03 Mn |
| Mar 31, 2022 | 469.74 Mn |
| Dec 31, 2021 | 471.32 Mn |
| Sep 30, 2021 | 502.86 Mn |